MEN1 and acute myeloid leukemia: This resistance mechanism is likely to depend on the site of binding of MI to Menin, binding avidity, and/or potency, thereby suggesting that treatment with a rational MI-based synergistic combination might be effective in eliminating the otherwise MI-resistant AML clone and prevent relapse with the therapy-refractory AML.